Masimo Corporation (MASI) revealed that Rochester General Health System and its 528-bed Rochester General Hospital have installed Masimo Patient SafetyNet system that combines Masimo SET pulse oximetry with ventilation monitoring and wireless clinician notification. The Masimo Patient SafetyNet system has been widely used by health care providers around the world as it is used in ensuring patient’s safety need.
Masimo Patient SafetyNet is a remote monitoring and clinician notification system. It measures and monitors patient’s physiological conditions and changes that indicate declining health status in real-time. When changes occur in the measured values and indicate deterioration in the patient's condition, the system automatically sends wireless alerts directly to clinicians and immediately leads to lifesaving response to the patient's bedside.
Further, the Masimo SET provides excellent support to clinicians to reduce retinopathy of prematurity (ROP) in neonates, screen newborns for Critical Congenital Heart Disease (:CCHD), as well as perform other functions to improve patient outcome in a cost-effective manner.
Masimo Patient SafetyNet has been installed in Rochester General Hospital after an extensive evaluation process that led to standardization of Masimo SET Measure-Through Motion and Low Perfusion pulse oximetry in the organization. The performance of Masimo SET pulse oximetry has been proved by more than 100 independent and objective studies and thousands of clinical evaluations.
According to the U.S. News & World Report Best Hospitals Honor Roll, MASI’s popular Masimo SET is used in 8 out of the top 10 hospitals to monitor more than 100 million patients annually. Its accurate measurements, along with increased specificity as well as sensitivity, help identify fatal breathing difficulties even during patient motion and low perfusion rate.
Earlier, Masimo had forged an agreement with University Children's Hospital in Basel, Switzerland. The hospital was the first pediatric institution in the region to utilize the Masimo Patient SafetyNet in its general wards.
Masimo Patient SafetyNet faces strong competition from Covidien’s (COV) Nellcor pulse oximeters. The company has started labeling the device to promote the usefulness of the product line for CCHD screening in infants. Moreover, the Food and Drug Administration (:FDA) has approved Covidien’s Nellcor Bedside SpO2 Patient Monitoring System, Bedside Respiratory Patient Monitoring System, and N-600x Pulse Oximetry Monitoring System for motion tolerance.
Currently, Masimo has a Zacks Rank #3 (Hold). Other medical instruments stocks that are worth considering include Delcath Systems, Inc. (DCTH) and Echo Therapeutics, Inc. (ECTE). Both of them carry a Zacks Rank #2 (Buy).